Vemurafenib in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

This study is currently recruiting participants. (see Contacts and Locations)
Verified February 2014 by University of California, San Francisco
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Theodore Nicolaides MD, University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT01748149
First received: December 7, 2012
Last updated: February 14, 2014
Last verified: February 2014
  Purpose

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E mutation.


Condition Intervention Phase
Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
Drug: Vemurafenib
Phase 0

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: PNOC 002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Primary Outcome Measures:
  • Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: Yes ]
    To determine if the maximum tolerated dose of vemurafenib established in adults is safe and tolerable in pediatric patients with BRAFV600E-mutant gliomas. (Dose is adjusted for pediatric use. Weighted dose extrapolated from FDA approved standard adult dose)

  • Toxicity Profile (dose limiting toxicities) [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: Yes ]

    To describe the toxicity profile/dose limiting toxicity of vemurafenib in children with recurrent or refractory glioma. DLT will be assessed by monitoring for adverse events, scheduled laboratory assessments, vital sign measurements, ECGs, and physical examinations. The severity of the toxicities will be graded according to the NCI CTCAE v 4.0. Adverse events and clinically significant laboratory abnormalities (meeting Grade 3, 4, or 5 criteria according to CTCAE) will be summarized by maximum intensity and relationship to study drug. Safety will be assessed weekly for the first 4 weeks and then every 4 weeks. Descriptive statistics will be utilized to display the data on toxicity seen.

    Safety will be assessed weekly for the first 4 weeks and then every 4 weeks. Descriptive statistics will be utilized to display the data on toxicity seen.


  • Concentrations of vemurafenib in the blood found through pharmacokinetic samples [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: Yes ]

    Venous blood samples (2 mL) will be collected in sodium heparin to measure concentrations of vemurafenib for each PK blood collection.

    To characterize the pharmacokinetics of vemurafenib in pediatric patients. Plasma drug concentrations and pharmacokinetic parameters will be presented in tabular and graphical form. Mandatory plasma pharmacokinetic studies will be performed in all patients enrolled on the MTD, pre-surgical, and "crushed" pill cohorts of this trial. Because the pharmacokinetics of this agent are unknown in the pediatric population, this information will be essential for evaluating toxicity and disease response and for refining dosing in future clinical trials of vemurafenib.


  • Objective Response [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: No ]
    To document antitumor activity of treatment with vemurafenib, as measured by objective responses.Objective response will be assessed using the RECIST Response criteria. The response will be collected on CRFs. The study team will include CR's, PR's and sustained stable disease (SSD- defined as stable disease on two successive scans). The target response rate is 20%. The number and percent of subjects with each type of response will be summarized and presented in data listings.


Secondary Outcome Measures:
  • Intra-tumoral drug concentration Comparison [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: Yes ]
    Subsequent to the safety cohort, the study team will begin enrollment into a presurgical study. Patients who are candidates for surgical resection at the time of relapse, would be eligible for this component of the trial. The aim will be to measure drug levels (based on the dose chosen in the safety cohort) in tumor, with an additional aim to describe target modulation, with vemurafenib treated tumor compared with corresponding archived tissue from prior surgery. Tumor phospho-ERK levels will be used as a molecular readout for agent activity. Drug levels will be measured by liquid chromatography/Mass spec. The statistical analysis will be descriptive and will be limited to frequency tables and summary statistics.

  • Progression-free survival [ Time Frame: Up to 6 months ] [ Designated as safety issue: Yes ]
    Progression-free survival at 6 months (PFS6) is defined as the proportion of patients alive and progression-free 180 days after Study Day 1. Duration of PFS is defined as the time from Study Day 1 to the earlier of disease progression or death due to any cause. All patients included in the study must be assessed for PFS6, even if there are major protocol treatment deviations or if they are ineligible.


Other Outcome Measures:
  • Levels of Phospho-ERK Comparison [ Time Frame: Up to 4 weeks ] [ Designated as safety issue: Yes ]
    To examine the levels of Phospho-ERK in patient tumor tissue during vemurafenib therapy then compare those to archived tissue on the same patient.


Estimated Enrollment: 54
Study Start Date: February 2014
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vemurafenib

Vemurafenib should be swallowed whole with 8 oz (1 cup) of water. Pharmacokinetic studies will determine if vemurafenib can be "crushed". If patients receiving "crushed" tablets are felt to receive adequate exposure, then they will be allowed to participate in the expansion cohort. [Patients approved to take "crushed" tablets should use a pill crusher and mix pill with 3-5 ml apple sauce]. If not, then only patients able to swallow whole pills will be eligible.

The patient will be requested to maintain a medication diary of each dose of medication. The medication diary will be returned to clinic staff at the end of each cycle.

Drug: Vemurafenib

Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg BID. Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.

Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery.

Other Names:
  • Vemurafenib
  • RO5185426
  • PLX4032

Detailed Description:

This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E mutation. Using the RP2D, the study team will then conduct a Phase 0 study in a pre-surgical cohort of 10 patients requiring debulking surgery at the time of recurrence. These patients will receive neo-adjuvant vemurafenib, thus allowing the study team to measure intra-tumoral drug concentrations and target inhibition. An expansion cohort will then be enrolled to allow the study team to preliminarily estimate efficacy.

  Eligibility

Ages Eligible for Study:   up to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with histologically confirmed diagnosis of glioma (WHO Grades I-IV) will be eligible. Patient tumors must test positive for the BRAFV600E mutation at UCSF Molecular Pathology central laboratory. If mutation cannot be confirmed from a prior test and archival tumor is not available to confirm presence of BRAFV600E mutation, patients must have tumor biopsy to collect tumor sample for mutation confirmation.
  • Patient must be less than 18 years of age at registration for the safety study. Patients must be < 25 years of age for Phase 0 and Efficacy Cohorts.
  • Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to registration.
  • Patients must be able to swallow tablets (or applesauce, if part of bioavailability "crushed" six patient cohort).
  • Patient must have MR imaging performed within two weeks of first dose of drug.
  • Karnofsky Performance Scale (KPS for > 16 yrs of age) or Lansky Performance Score(LPS for ≤ 16 years of age) ≥ 60 assessed within two weeks prior to registration.
  • The patient must have failed at least one prior therapy besides surgery- radiation or chemotherapy (either cytotoxic or biologic agent)- prior to study registration. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study.
  • Myelosuppressive chemotherapy: Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosourea.
  • Biologic agent: Patient must have recovered from any toxicity potentially related to the agent and received their last dose of the biologic agent ≥ 7 days prior to study registration.
  • For agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur. The duration of this interval should be discussed with the study chair.
  • For biologic agents that have a prolonged half-life, the appropriate interval since last treatment should be discussed with the study chair prior to registration.
  • Monoclonal antibody treatment: At least three half-lives must have elapsed prior to registration. Such patients should be discussed with the study chair prior to registration.
  • Radiation: Patients must have:
  • Had their last fraction of local irradiation to primary tumor ≥12 weeks prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression.
  • Had their last fraction of craniospinal irradiation or total body irradiation > 12 weeks prior to registration
  • Bone Marrow Transplant: Patient must be:
  • ≥ 6 months since allogeneic bone marrow transplant prior to registration
  • ≥ 3 months since autologous bone marrow/stem cell prior to registration
  • Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration.
  • Growth factors: Off all colony forming growth factor(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long- acting formulations.
  • Organ Function: Documented within 14 days of registration and within 7 days of the start of treatment.
  • Adequate bone marrow function:
  • Absolute neutrophil count ≥ 1000/μl (unsupported)
  • Platelets ≥ 75,000/μl (unsupported)
  • Hemoglobin ≥ 8 g/dL (may be supported)
  • Adequate hepatic function:
  • Total bilirubin < 1.5 times upper limit of normal for age
  • SGPT/SGOT (ALT/AST) ≤ 2.5 times institutional upper limit of normal for age
  • Adequate renal function:
  • Creatinine clearance or Radioisotope GFR ≥ 70 ml/min/1.73m2 or a serum creatinine based on age as follows: Less than or equal to 5 years of age= Maximum Serum Creatinine (mg/dL)of 0.8; Older than 5 but 10 years or younger= Maximum Serum Creatinine (mg/dL)of 1.0; Older than 10 but 15 years or younger= Maximum Serum Creatinine (mg/dL)of 1.2; Older than 15 years= Maximum Serum Creatinine (mg/dL) of 1.5
  • Electrolytes:
  • Sodium: ≥ 130 and ≤ 145 mmol/L
  • Potassium: 3.4- 4.8 mmol/L
  • Calcium: ≥ 7 mg/dL
  • Magnesium: ≥ 0.7 mmol/L
  • Nutrition:
  • Albumin ≥ 3 g/dL
  • Cardiac:
  • QTc interval <450 msec on EKG.
  • Female patients of childbearing potential must not be pregnant or breast-feeding. Female patients of childbearing potential must have a negative serum or urine pregnancy test. The effects of Vemurafenib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception: (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, and for four weeks after dosing with vemurafenib ceases. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 weeks after completion of study drug administration.
  • All skin lesions suspicious for keratoacanthomas/cSCC found at baseline dermatology visit must have been excised.
  • Signed informed consent according to institutional guidelines must be obtained.

Specific inclusion criteria for Pre-Surgical Cohort:

  • Patients under 25 years of age will be eligible for the pre-surgical cohort. Patients between 18-25 years of age will be treated at the adult FDA-approved dose of 960 mg BID and can be enrolled immediately. Patients less than 18 years of age will be enrolled and treated at the pediatric MTD once it is defined in the Safety Cohort.
  • Surgical patients must have tumor that needs to be removed/debulked and is accessible for the neurosurgeon. Need for surgery must be such that the patient can take drug for 10 days before surgery.

Specific inclusion criteria for Expansion cohort:

• Expansion cohort will be open if tissue drug levels in the Pre-Surgical cohort meet criteria (Tumor tissue drug concentration is greater than 50 nM). Patients under 25 years of age will be eligible for the expansion cohort. Patients between 18 and 25 years of age will take adult dose of 960 mg BID. Patients less than 18 years of age will take the MTD defined in the safety cohort.

Exclusion Criteria:

  • Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction) that will likely interfere with the study procedures or results.
  • All patients with known clinical diagnosis of Neurofibromatosis Type 1 are excluded.
  • Patients receiving any other anticancer or investigational drug therapy.
  • Patients with uncontrolled seizures are not eligible for the study.
  • Previous BRAF inhibitor use such as vemurafenib, GSK2118436 or sorafenib.
  • Patients with QTc interval >450 msecs or other factors that increase the risk of QTprolongation or arrhythmic events (e.g., heart failure, hypokalemia, family history of long QT interval syndrome) including heart failure that meets New York Heart Association(NYHA) class III and IV definitions are excluded.
  • Required use of a concomitant medication that can prolong the QT interval. A comprehensive list of agents with the potential to cause QTc prolongation can be found at http://www.azcert.org/medical-pros/drug-lists/browse-drug-list.cfm?alpha=A
  • Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to vemurafenib.
  • Negative result of BRAFV600E screening test performed at UCSF.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01748149

Contacts
Contact: Theodore Nicolaides, MD 415-476-3831 theodore.nicolaides@ucsf.edu

Locations
United States, California
Children's Hospital Los Angeles Not yet recruiting
Los Angeles, California, United States, 90027
Contact: Ghirish Dhall, MD    323-361-8147    GDhall@chla.usc.edu   
Contact: Jonathan Finlay, MD    323-361-8147    JFinlay@chla.usc.edu   
Principal Investigator: Ghirish Dhall, MD         
Sub-Investigator: Jonathan Finlay, MD         
University of California, Los Angeles Not yet recruiting
Los Angeles, California, United States, 90027
Contact: Tom B Davidson, MD    310-825-6708    tdavidson@mednet.ucla.edu   
Principal Investigator: Tom B Davidson, MD         
Children's Hospital Oakland Not yet recruiting
Oakland, California, United States, 94609
Contact: Joseph Torkildson, MD    510-428-3272    jtorkildson@mail.cho.org   
Contact: Caroline Hastings, MD    (510) 428-3272    chastings@mail.cho.org   
Principal Investigator: Joseph Torkildson, MD         
Sub-Investigator: Caroline Hastings, MD         
University of California, San Diego Rady Children's Hospital Not yet recruiting
San Diego, California, United States, 92123
Contact: John Crawford, MD    858-966-4930    jrcrawford@rchsd.org   
Contact: Michael Levy, MD    858-966-4930    mlevy@rchsd.org   
Principal Investigator: John Crawford, MD         
Sub-Investigator: Michael Levy, MD         
University of California, San Francisco Recruiting
San Francisco, California, United States, 94115
Contact: Theodore Nicolaides, MD    415-476-3831    theodore.nicolaides@ucsf.edu   
Principal Investigator: Theodore Nicolaides, MD         
Sub-Investigator: Sabine Mueller, MD, PhD         
United States, Oregon
Oregon Health & Science University Not yet recruiting
Portland, Oregon, United States, 97239
Contact: Kellie Nazemi, MD    503-494-1543    nazemik@ohsu.edu   
Principal Investigator: Kellie Nazemi, MD         
United States, Utah
University of Utah Not yet recruiting
Salt Lake City, Utah, United States, 84112
Contact: Richard Lemons, MD    801-662-4700    richard.lemons@intermountainmail.org   
Contact: Carol Bruggers, MD    801-662-4700    carol.bruggers@imail.org   
Principal Investigator: Richard Lemons, MD         
Sub-Investigator: Carol Bruggers, MD         
United States, Washington
University of Washington, Seattle Not yet recruiting
Seattle, Washington, United States, 98195
Contact: Sarah Leary, MD    206-667-7955    sarah.leary@seattlechildrens.org   
Contact: Russ Geyer, MD    206-667-7955    russ.geyer@seattlechildrens.org   
Sub-Investigator: Russ Geyer, MD         
Principal Investigator: Sarah Leary, MD         
Sponsors and Collaborators
Theodore Nicolaides MD
Genentech, Inc.
Investigators
Principal Investigator: Theodore Nicolaides, MD University of California, San Francisco
  More Information

No publications provided

Responsible Party: Theodore Nicolaides MD, Assistant Adjunct Professor, Pediatric Hematology/Oncology, University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01748149     History of Changes
Other Study ID Numbers: CC#120819
Study First Received: December 7, 2012
Last Updated: February 14, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by University of California, San Francisco:
recurrent/refractory BRAFV600E-mutant gliomas
pediatrics
children
neo-adjuvant vemurafenib

Additional relevant MeSH terms:
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors

ClinicalTrials.gov processed this record on October 29, 2014